Glaukos Corp Ownership
| GKOS Stock | USD 112.72 2.02 1.82% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 48.9 M | Current Value 49.6 M | Avarage Shares Outstanding 38.7 M | Quarterly Volatility 9.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Glaukos |
Glaukos Stock Ownership Analysis
About 97.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.64. Glaukos Corp recorded a loss per share of 2.88. The entity had not issued any dividends in recent years. Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California. Glaukos Corp operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 727 people. To learn more about Glaukos Corp call Thomas Burns at 949 367 9600 or check out https://www.glaukos.com.Besides selling stocks to institutional investors, Glaukos Corp also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Glaukos Corp's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Glaukos Corp's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Glaukos Corp Quarterly Liabilities And Stockholders Equity |
|
Glaukos Corp Insider Trades History
Roughly 3.0% of Glaukos Corp are currently held by insiders. Unlike Glaukos Corp's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Glaukos Corp's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Glaukos Corp's insider trades
Glaukos Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Glaukos Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Glaukos Corp backward and forwards among themselves. Glaukos Corp's institutional investor refers to the entity that pools money to purchase Glaukos Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Artisan Partners Limited Partnership | 2024-03-31 | 1.2 M | Ameriprise Financial Inc | 2023-12-31 | 1.1 M | Geode Capital Management, Llc | 2023-12-31 | 1 M | Dimensional Fund Advisors, Inc. | 2024-03-31 | 918.2 K | Primecap Management Company | 2024-03-31 | 848.6 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 662.3 K | Driehaus Capital Management Llc | 2024-03-31 | 648 K | Capital World Investors | 2024-03-31 | 550.3 K | Northern Trust Corp | 2023-12-31 | 542.7 K | Blackrock Inc | 2023-12-31 | 7.9 M | Fmr Inc | 2023-12-31 | 5.8 M |
Glaukos Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Glaukos Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Glaukos Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Glaukos Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Marc Stapley over two weeks ago Disposition of 6250 shares by Marc Stapley of Glaukos Corp at 32.0 subject to Rule 16b-3 | ||
Tomas Navratil over three weeks ago Acquisition by Tomas Navratil of 11075 shares of Glaukos Corp subject to Rule 16b-3 | ||
Alex Thurman over a month ago Disposition of tradable shares by Alex Thurman of Glaukos Corp at 92.74 subject to Rule 16b-3 | ||
Tomas Navratil over two months ago Disposition of 2603 shares by Tomas Navratil of Glaukos Corp at 88.72 subject to Rule 16b-3 | ||
Tomas Navratil over two months ago Acquisition by Tomas Navratil of 1950 shares of Glaukos Corp subject to Rule 16b-3 | ||
Gilbert Kliman over two months ago Disposition of 5202 shares by Gilbert Kliman of Glaukos Corp at 84.93 subject to Rule 16b-3 | ||
Aimee Weisner over three months ago Acquisition by Aimee Weisner of 895 shares of Glaukos Corp subject to Rule 16b-3 | ||
Aimee Weisner over a year ago Exercise or conversion by Aimee Weisner of 10000 shares of Glaukos Corp subject to Rule 16b-3 |
Glaukos Corp Corporate Filings
| 30th of May 2024 Other Reports | ViewVerify | |
8K | 20th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 16th of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 3rd of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Pair Trading with Glaukos Corp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Glaukos Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Glaukos Corp will appreciate offsetting losses from the drop in the long position's value.Moving together with Glaukos Stock
| 0.68 | ESTA | Establishment Labs | PairCorr |
Moving against Glaukos Stock
| 0.93 | CAH | Cardinal Health Fiscal Year End 20th of August 2024 | PairCorr |
| 0.92 | VMD | Viemed Healthcare | PairCorr |
| 0.91 | CVS | CVS Health Corp Buyout Trend | PairCorr |
| 0.91 | SSY | SunLink Health Systems | PairCorr |
| 0.89 | XTNT | Xtant Medical Holdings | PairCorr |
The ability to find closely correlated positions to Glaukos Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Glaukos Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Glaukos Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Glaukos Corp to buy it.
The correlation of Glaukos Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Glaukos Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Glaukos Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Glaukos Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Glaukos Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Glaukos Stock please use our How to Invest in Glaukos Corp guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Glaukos Stock analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stocks Directory Find actively traded stocks across global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Glaukos Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Glaukos Corp. If investors know Glaukos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Glaukos Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 18.963 | Earnings Share (2.88) | Revenue Per Share 6.681 | Quarterly Revenue Growth 0.159 | Return On Assets (0.08) |
The market value of Glaukos Corp is measured differently than its book value, which is the value of Glaukos that is recorded on the company's balance sheet. Investors also form their own opinion of Glaukos Corp's value that differs from its market value or its book value, called intrinsic value, which is Glaukos Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Glaukos Corp's market value can be influenced by many factors that don't directly affect Glaukos Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Glaukos Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Glaukos Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Glaukos Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.